GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>it is simpler to target specific glycosylation sites you want modified in a construct (as they outline here) than to modify the factory(goat) which in turn will alter not just the glycosylation of your product, but glycosylation states of every protein in the whole damn goat.<

Because such global transformation entails the possibility
of unexpected untoward consequences?

>it interacts, e. g., binds heparin tighter than wild type ATIII<

Do I have this right, the steric change makes the normally
concealed moiety (hook) out and about more of the time?
Like with smaller pillows under your hindquarters and
shoulders your back spends more time arched in the preferred
curve?